摘要
目的探讨多发性骨髓瘤患者IgGκ、IgGλ水平及IgGκ/IgGλ比值测定对预后判断的意义。方法采用HevyliteTM法测定18例多发性骨髓瘤患者及30例健康者血清IgGκ、IgGλ水平,并进行随访,计算不同IgGκ、IgGλ水平和IgGκ/IgGλ比值患者1年和3年总体生存率。结果上述多发性骨髓瘤患者血清IgGκ、IgGλ水平的中位数分别为25.90、24.35g/L,高于健康者。上述患者1年和3年的总体生存率的比较,IgGκ/IgGλ在0.4～13范围的患者高于IgGκ/IgGλ<0.40或大于13的患者(P<0.05);IgGκ<23.70g/L或IgGλ<22.15g/L的患者高于IgGκ≥23.70g/L或IgGλ≥22.15g/L的患者(P<0.05)。结论血清IgGκ、IgG水平及其比值测定有助于多发性骨髓瘤患者预后的判断。
Objective To investigate the significance of IgGκ ,IgGλ levels and IgGκ ,IgGλ ratios measurements in prognosis for pa- tients with multiple myeloma. Methods HevyliteTM assay was used to Determine the IgGκ ,IgGλ levels of 18 cases of multiple mye- loma patients and 30 healthy people,who were followed up for 1- 3 years. Overall survival rates were calculated for patients with different levels of IgGκ ,IgGλ and IgGκ ,IgGλ ratio. Results The median levels of IgGκ ,IgGλ for the patients mentioned above were 25.90 and 24.35 g/L respectively,which were above the normal range. In the patients＇ 1 and 3-year overall survival rate compari- son,there was a higher rate for patients with IgGκ ,IgGλ in the range of 0.40 to 13 than 〈（0.40 or than（P〈0.05）;a higher rate was also observed for patients with IgGκ23.70 g/L or IgGλ22.15 g/L than IgGκ23.70 g/L or IgGλ22.15 g/L（P〈0. 05）. Conclusion Serum IgGκ ,IgGλ levels and their ratio helps determine the prognosis of patients with multiple myeloma.
出处
《国际检验医学杂志》
CAS
2013年第15期1971-1972,共2页
International Journal of Laboratory Medicine
